SFM
CRNX icon

Sphera Funds Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Sphera Funds Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-82,747
Closed -$1.33M – 90
2023
Q1 		$1.33M Sell
82,747
-588,897
-88% -$10.9M 0.22% 66
2022
Q4 		$12.3M Buy
671,644
+45,092
+7% +$795K 2.64% 9
2022
Q3 		$12.3M Buy
626,552
+39,732
+7% +$810K 1.71% 13
2022
Q2 		$10.9M Buy
586,820
+64,873
+12% +$1.29M 1.17% 18
2022
Q1 		$11.5M Buy
521,947
+98,699
+23% +$2M 1.62% 18
2021
Q4 		$12M Sell
423,248
-125,395
-23% -$3.09M 1.32% 23
2021
Q3 		$11.5M Sell
548,643
-85,445
-13% -$1.79M 0.97% 27
2021
Q2 		$12M Buy
634,088
+349,864
+123% +$6.15M 0.81% 37
2021
Q1 		$4.34M Buy
+284,224
New +$4.41M 0.33% 78

Other funds holding CRNX

DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sphera Funds Management's CRNX Position: Q2 2023 in Review

Sphera Funds Management sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2023, closing a stake of 82,747 shares — an estimated $1.33M sold.

Sphera Funds Management first reported a position in CRNX in Q1 2021 and held it in 9 quarters. The position peaked at $12.3M in Q3 2022. 140 funds tracked by Wall St. Rank hold CRNX as of Q2 2023.

  • Sphera Funds Management reported no remaining Crinetics Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Sphera Funds Management sold 82,747 Crinetics Pharmaceuticals shares in Q2 2023, an estimated $1.33M.
  • Sphera Funds Management first reported a position in Crinetics Pharmaceuticals in Q1 2021 and held it in 9 quarters.
  • Sphera Funds Management's Crinetics Pharmaceuticals position peaked at $12.3M in Q3 2022.
  • 140 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2023.

Based on Sphera Funds Management's 13F filing for Q2 2023, filed 14 Aug 2023.